A review of the case for hepatitis B vaccination of high-risk adults

Rich, Josiah D.; Ching, Catherine G; Lally, Michelle; Gaitanis, Melissa; Schwartzapfel, Beth; Charuvastra, Anthony; Beckwith, Curt G.; Flanigan, Timothy P.

doi:10.1016/s0002-9343(02)01560-7

Cited by 52 publications

(43 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to date, no specific therapy is available for chronic hepatitis B. The following factors may be associated with its pathogenesis such as virulence of HBV strains, number of infected hepatocytes and host immune response, antiviral agents, immunomodulators and drugs might be capable of improving liver function [12][13][14][15][34][35][36][37][38][39][40][41] . Traditional Chinese medicine has been widely used for the treatment of liver disease in China [11] .…”

Section: Discussionmentioning

confidence: 99%

Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial

Lu¹,

Zeng²,

Mao³

et al. 2003

WJG

View full text Add to dashboard Cite

AIM:To evaluate the efficacy and safety of capsule oxymatrine in the treatment of chronic hepatitis B. METHODS:A randomised double-blind and placebocontrolled multicenter trial was conducted. Injection of oxymatrine was used as positive-control drug. A total of 216 patients with chronic hepatitis B entered the study for 24 weeks, of them 108 received capsule oxymatrine, 36 received injection of oxymatrine, and 72 received placebo. After and before the treatment, clinical symptoms, liver function, serum hepatitis B virus markers, and adverse drug reaction were observed. RESULTS:Among the 216 patients, six were dropped off, and 11 inconsistent with the standard were excluded. Therefore, the efficacy and safety of oxymatrine in patients were analysed. In the capsule treated patients, 76.47 % became normal in ALT level, 38.61 % and 31.91 % became negative both in HBV DNA and in HBeAg. In the injection treated patients, 83.33 % became normal in ALT level, 43.33 % and 39.29 % became negative both in HBV DNA and in HBeAg. In the placebo treated patients, 40.00 % became normal in ALT level, 7.46 % and 6.45 % became negative both in HBV DNA and in HBeAg. The rates of complete response and partial response were 24.51 % and 57.84 % in the capsule treated patients, and 33.33 % and 50.00 % in the injection treated patients, and 2.99 % and 41.79 % in the placebo treated patients, respectively. There was no significance between the two groups of patients, but both were significantly higher than the placebo. The adverse drug reaction rates of the capsule, injection and placebo were 7.77 %, 6.67 % and 8.82 %, respectively. There was no statistically significant difference among them. CONCLUSION:Oxymatrine is an effective and safe agent for the treatment of chronic hepatitis B.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial

Lu¹,

Zeng²,

Mao³

et al. 2003

WJG

View full text Add to dashboard Cite

show abstract

“…There is now a strong realization that prisons provide an excellent opportunity for the delivery of hepatitis B vaccination, and a number of reports from England, France, Spain and the United States report both largeand small-scale projects delivering accelerated vaccination programmes [9][10][11][12][13].…”

mentioning

confidence: 99%

“…However, other work indicates that vaccination is required early, ideally in adolescence, to achieve the greatest effect [15].…”

mentioning

confidence: 99%

“…It will also prevent a substantial number of liver cancers in the long term and can be delivered effectively for a modest investment. The hepatitis B vaccine is efficacious, safe and cost-effective [16], but has been under-utilized consistently in high-risk adults despite long-standing recommendations [15]. Instituting routine hepatitis B vaccination for high-risk adults in settings such as prisons and jails could prevent up to 800 cases of hepatitis and 10 deaths from hepatitis per 10 000 vaccinations, with overall cost savings [14,15].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B vaccination in prisons: a much‐needed targeted universal intervention

FARRELL,

STRANG,

STÖVER

2010

Addiction

View full text Add to dashboard Cite

“…5,6 Integration of hepatitis vaccination in settings serving those at highest risk is challenging, and a lack of dedicated federal funding for support of vaccines for adults is a significant barrier. 5,[7][8][9][10][11] Missed opportunities to vaccinate adults in various settings abound. 5,[7][8][9][10] This article describes a statewide program to provide hepatitis A and B vaccination to adults at high risk.…”

mentioning

confidence: 99%

Expansion of Adult Hepatitis A and B Vaccination in STD Clinics and other Settings in New York State

et al. 2007

View full text Add to dashboard Cite

Since 1995, the New York State (NYS) Adult Hepatitis Vaccination Program has promoted adult hepatitis B vaccination for those receiving sexually transmitted disease (STD) clinic services. An average of 6,333 doses was administered annually from 1995 to 1999. By 2000, only 15 of 57 county STD programs in NYS outside of New York City participated. From 2000 to 2005, efforts to enroll county health departments and others included outreach, provision of hepatitis A and B vaccine, materials and training, and new collaborations. All 57 counties now participate. From 2000 to 2005, the number of settings offering hepatitis vaccination increased from 57 to 119. Sites include STD clinics; jails; migrant, Indian health, and college health centers; and methadone clinics. More than 125,000 doses of hepatitis A and B vaccine were administered from 1995 through 2005, with annual increases up to a high of 21,025 doses in 2005. Intensive promotion expanded hepatitis vaccination to all county STD clinics and other settings where high-risk adults can be vaccinated.

show abstract

A review of the case for hepatitis B vaccination of high-risk adults

Cited by 52 publications

References 19 publications

Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial

Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial

Hepatitis B vaccination in prisons: a much‐needed targeted universal intervention

Expansion of Adult Hepatitis A and B Vaccination in STD Clinics and other Settings in New York State

Contact Info

Product

Resources

About